Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies

Shuanghui Yang; Huan Li; Ling Xu; Zhenhan Deng; Wei Han; Yanting Liu; Wenqi Jiang; Youli Zu

doi:10.1016/j.omtn.2018.08.023

Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies

Shuanghui Yang, Huan Li, Ling Xu, Zhenhan Deng, Wei Han, Yanting Liu, Wenqi Jiang, Youli Zu

Research output: Contribution to journal › Review article › peer-review

25 Scopus citations

Abstract

Precision medicine has recently emerged as a promising strategy for cancer therapy because it not only specifically targets cancer cells but it also does not have adverse effects on normal cells. Oligonucleotide aptamers are a class of small molecule ligands that can specifically bind to their targets on cell surfaces with high affinity. Aptamers have great potential in precision cancer therapy due to their unique physical, chemical, and biological properties. Therefore, aptamer technology has been widely investigated for biomedical and clinical applications. This review focuses on the potential applications of aptamer technology as a new tool for precision treatment of hematological malignancies, including leukemia, lymphoma, and multiple myeloma.

Original language	English (US)
Pages (from-to)	164-175
Number of pages	12
Journal	Molecular Therapy - Nucleic Acids
Volume	13
DOIs	https://doi.org/10.1016/j.omtn.2018.08.023
State	Published - Dec 7 2018

Keywords

aptamer
leukemia
lymphoma
multiple myeloma
precision medicine

ASJC Scopus subject areas

Molecular Medicine
Drug Discovery

Access to Document

10.1016/j.omtn.2018.08.023

Cite this

@article{0b258506e6de44109e44bbb0f62e9d4f,

title = "Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies",

abstract = "Precision medicine has recently emerged as a promising strategy for cancer therapy because it not only specifically targets cancer cells but it also does not have adverse effects on normal cells. Oligonucleotide aptamers are a class of small molecule ligands that can specifically bind to their targets on cell surfaces with high affinity. Aptamers have great potential in precision cancer therapy due to their unique physical, chemical, and biological properties. Therefore, aptamer technology has been widely investigated for biomedical and clinical applications. This review focuses on the potential applications of aptamer technology as a new tool for precision treatment of hematological malignancies, including leukemia, lymphoma, and multiple myeloma.",

keywords = "aptamer, leukemia, lymphoma, multiple myeloma, precision medicine",

author = "Shuanghui Yang and Huan Li and Ling Xu and Zhenhan Deng and Wei Han and Yanting Liu and Wenqi Jiang and Youli Zu",

year = "2018",

month = dec,

day = "7",

doi = "10.1016/j.omtn.2018.08.023",

language = "English (US)",

volume = "13",

pages = "164--175",

journal = "Molecular Therapy - Nucleic Acids",

issn = "2162-2531",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies

AU - Yang, Shuanghui

AU - Li, Huan

AU - Xu, Ling

AU - Deng, Zhenhan

AU - Han, Wei

AU - Liu, Yanting

AU - Jiang, Wenqi

AU - Zu, Youli

PY - 2018/12/7

Y1 - 2018/12/7

N2 - Precision medicine has recently emerged as a promising strategy for cancer therapy because it not only specifically targets cancer cells but it also does not have adverse effects on normal cells. Oligonucleotide aptamers are a class of small molecule ligands that can specifically bind to their targets on cell surfaces with high affinity. Aptamers have great potential in precision cancer therapy due to their unique physical, chemical, and biological properties. Therefore, aptamer technology has been widely investigated for biomedical and clinical applications. This review focuses on the potential applications of aptamer technology as a new tool for precision treatment of hematological malignancies, including leukemia, lymphoma, and multiple myeloma.

AB - Precision medicine has recently emerged as a promising strategy for cancer therapy because it not only specifically targets cancer cells but it also does not have adverse effects on normal cells. Oligonucleotide aptamers are a class of small molecule ligands that can specifically bind to their targets on cell surfaces with high affinity. Aptamers have great potential in precision cancer therapy due to their unique physical, chemical, and biological properties. Therefore, aptamer technology has been widely investigated for biomedical and clinical applications. This review focuses on the potential applications of aptamer technology as a new tool for precision treatment of hematological malignancies, including leukemia, lymphoma, and multiple myeloma.

KW - aptamer

KW - leukemia

KW - lymphoma

KW - multiple myeloma

KW - precision medicine

UR - http://www.scopus.com/inward/record.url?scp=85054186384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054186384&partnerID=8YFLogxK

U2 - 10.1016/j.omtn.2018.08.023

DO - 10.1016/j.omtn.2018.08.023

M3 - Review article

AN - SCOPUS:85054186384

SN - 2162-2531

VL - 13

SP - 164

EP - 175

JO - Molecular Therapy - Nucleic Acids

JF - Molecular Therapy - Nucleic Acids

ER -

Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this